Pierre Fabre and Lonza Enter Manufacturing Agreement for W0180 Antibody Drug Product – QNT Press Release

  • Lonza will provide clinical drug product manufacturing for W0180, an oncology drug candidate discovered by Pierre Fabre targeting solid tumors, from its fill and finish facility in Stein, Switzerland
  • Pierre Fabre will leverage Lonza’s drug product expertise and fill and finish capabilities

TOULOUSE, France, June 15, 2022 /PRNewswire/ — Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, and French pharmaceutical group Pierre Fabre announced today that the companies have entered into a manufacturing agreement.

This collaboration is aimed at manufacturing W0180, an innovative monoclonal antibody discovered by

Full story available on Benzinga.com

Source link

Recommended For You

About the Author: News Center